Therefore, the LTC4/CysLT2R/15-PGDH signalling-mediated downregulation of Hh–GLI1 signalling combined with increased redifferentiation could be an alternative therapeutic treatment in addition to classical chemotherapy for colon cancer patients (Fig. 7d). This evidence concerns the gene CYSLTR2 and colonic neoplasm.